CD163 and neoplasm: The immune populations of 235 PDAC patients were processed by mIHC for a panel of myeloid and lymphoid cell markers encompassing CD8+ T cells, CD4+ T cells, CD16+/CD163− (M1) macrophages and CD16+/CD163+ (M2) tumor-promoting macrophages.